Ultime notizie per Immix Biopharma (NASDAQ:IMMX) Azioni

Immix Biopharma

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Immix Biopharma Inc

<p><strong>2024 Financial Guidance</strong></p>
<p>Management reiterates its full year 2024 guidance:</p>
<ul>
<li>Anticipated Total Net Revenues expected to be between $87 million and $95 million;</li>
<li>Anticipated Operating Expenses expected to remain between $115 million and $120 million;</li>
<li>Anticipated Total Annual Cash Investment expected to remain between $15 million and $20 million; and</li>
<li>Cash and Cash Equivalents anticipated to continue to support operations as currently planned into 2027.</li>
</ul>


Biotech

Earnings

News

Guidance

Health Care

General

YMAB

Y-mAbs Anticipates 2024 Total Net Revenues Of $87M-$95M Vs. Consensus Of $91.67M

<p>Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) raises FY2024 Adj EPS guidance from $2.15-2.40 to $2.35-2.50 vs $2.20 analyst estimate. Raises FY2024 sales outlook from $1.63 billion-1.68 billion to $1.65 billion-1.68 billion vs $1.66 billion estimate.</p>


ATMU

Atmus Filtration Techs Raises FY2024 Adj EPS Guidance from $2.15-2.40 to $2.35-$2.50 vs $2.20 Est; Raises FY2024 Sales Guidance from $1.63B-$1.68B to $1.65B-$1.68B vs $1.66B Est

<p>Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.49 by 24.49 percent. This is a 17.31 percent increase over earnings of $0.52 per share from the same period last year.  The company reported quarterly sales of $403.70 million which beat the analyst consensus estimate of $403.41 million by 0.07 percent.  This is a 1.89 percent increase over sales of $396.20 million the same period last year.</p>


Earnings Beats

Atmus Filtration Techs Q3 Adj $0.61 Beats $0.49 Estimate, Sales $403.70M Beat $403.41M Estimate

<p>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. This is a 11.11 percent increase over losses of $(0.18) per share from the same period last year.  The company reported quarterly sales of $18.46 million which missed the analyst consensus estimate of $23.26 million by 20.64 percent.  This is a 9.74 percent decrease over sales of $20.45 million the same period last year.</p>


Y-mAbs Therapeutics Q3 2024 GAAP EPS $(0.16), Inline, Sales $18.46M Miss $23.26M Estimate

<p>On Thursday, November 8th, U.S. markets ended mixed after the Federal Reserve cut interest rates by 25 basis points, citing an eased job market and progress toward the 2% inflation target. Optimism over President-elect Donald Trump&#8217;s return lifted the S&amp;P 500 and Nasdaq to record highs, with global markets rallying in response.</p>
<p>Financials led declines among S&amp;P sectors, reversing strong gains from the previous session as bank stocks fell sharply.</p>
<p>The Federal Reserve cut rates by 0.25 points to a 4.5%-4.75% range, slowing the pace of easing from September&#8217;s 0.5% cut.</p>
<p>In economic data, U.S. initial jobless claims rose to 221,000 in late October, while Q3 nonfarm productivity increased by 2.2% and unit labor costs grew by 1.9%. Wholesale inventories fell 0.2% in September, and natural gas stocks climbed by 69 billion cubic feet to 3.932 trillion.</p>
<p>The Dow Jones Industrial Average was flat and closed at 43,729.34, the S&amp;P 500 rose 0.74% to 5,973.10, and the Nasdaq Composite soared 1.51% to finish at 19,269.46.</p>
<p><strong>Asia Markets Today</strong></p>
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 gained 0.19% and ended the session at 39,468.50, led by gains in the Textile, Shipbuilding and Steel sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 rose 0.84% and ended the day at 8,295.10, led by gains in the Gold, IT, and Consumer Discretionary sectors.     </li>
<li>India&#8217;s Nifty 50 traded lower by 0.21% at 24,148.20, and Nifty 500 was down 0.70% at 22,645.65.</li>
<li>China&#8217;s Shanghai Composite slid 0.53% to close at 3,452.30, and the Shenzhen CSI 300 declined 1.00%, finishing the day at 4,104.05.</li>
<li>Hong Kong&#8217;s Hang Seng fell 1.7% and closed the session at 20,728.19.</li>
</ul>
<p><strong>Eurozone at 05:30 AM ET</strong></p>
<ul>
<li>The European STOXX 50 index was down 1.09%.</li>
<li>Germany&#8217;s DAX declined 0.99%.</li>
<li>France&#8217;s CAC fell 1.13%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 0.72%.</li>
</ul>
<p><strong>Commodities at 05:30 AM ET</strong></p>
<ul>
<li>Crude Oil WTI was trading lower by 1.64% at $71.19/bbl, and Brent was down 1.35% at $74.62/bbl.</li>
<li>Oil prices edged lower as Hurricane Rafael&#8217;s impact on U.S. output eased and markets assessed Trump&#8217;s potential policies on global supply.</li>
<li>Natural Gas gained 0.63% to $2.710.</li>
<li>Gold was trading lower by 0.49% at $2,692.00, Silver fell 1.11% to $31.503, and Copper slipped 2.30% to $4.3290.</li>
</ul>
<p><strong>U.S. Futures at 05:30 AM ET</strong></p>
<p>Dow futures slipped 0.04%, S&amp;P 500 futures were down 0.03%, and Nasdaq 100 futures fell 0.14%.</p>
<p><strong>Forex at 05:30 AM ET</strong></p>
<ul>
<li>The U.S. dollar index declined 0.02% to 104.49, the USD/JPY was down 0.39% to 152.37, and the USD/AUD rose 0.68% to 1.5072.</li>
<li>The U.S. dollar edged higher this week, buoyed by &#8220;Trump trades&#8221; but tempered by policy uncertainty. The yen rose, and the Australian dollar logged solid weekly gains.</li>
</ul>
<p><em>Photo by Pavel Bobrovskiy via Shutterstock</em></p>


Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Mixed, Europe, Crude Oil, Gold And Dollar Cool Off - Global Markets Today While US Slept

STRW

Strawberry Fields REIT Registers Q3 AFFO Of $14.3M, Higher Than $11.5M YoY; Company Declared Cash Dividend Of $0.14 Per Share That Will Be Paid On December 30

<p>Phil Eyler to Remain as an Advisor to Gentherm through June 30, 2025.</p>


Management

THRM

Gentherm Plans CEO Succession In 2025; Bill Presley To Become President And CEO, And Board Director, As Of January 1, 2025

<p>JMP Securities  analyst Andrew Boone   downgrades Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) from Market Outperform to Market Perform.</p>


Downgrades

Analyst Ratings

NRDY

JMP Securities Downgrades Nerdy to Market Perform

<p>Graham (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHM#NYSE">GHM</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.14 by 121.43 percent. This is a 342.86 percent increase over earnings of $0.07 per share from the same period last year.  The company reported quarterly sales of $53.563 million which beat the analyst consensus estimate of $49.700 million by 7.77 percent.  This is a 18.83 percent increase over sales of $45.076 million the same period last year.</p>


Graham Q2 2025 Adj. EPS $0.31 Beats $0.14 Estimate, Sales $53.563M Beat $49.700M Estimate

<p>HSBC  analyst Daniel Yang   downgrades Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) from Buy to Hold and lowers the price target from $154 to $81.</p>


Price Target

ENPH

HSBC Downgrades Enphase Energy to Hold, Lowers Price Target to $81

<p>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.25 by 8 percent.  The company reported quarterly sales of $674.90 million which met the analyst consensus estimate.  This is a 13.07 percent decrease over sales of $776.40 million the same period last year.</p>


Earnings Misses

FTRE

Fortrea Holdings Q3 2024 Adj EPS $0.23 Misses $0.25 Estimate, Sales $674.90M Inline

<p>Guggenheim  analyst Seamus Fernandez   initiates coverage on Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) with a Buy rating and announces Price Target of $33.</p>


Initiation

CDTX

Guggenheim Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $33

<p>Piper Sandler  analyst Charles Neivert   downgrades Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from Neutral to Underweight and lowers the price target from $150 to $98.</p>


Piper Sandler Downgrades Celanese to Underweight, Lowers Price Target to $98

HIPO

Hippo Holdings Q3 Revenues Increases 65% YoY To $95M

<p>Daiwa Capital  analyst Jonathan Kees   upgrades AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) from Neutral to Outperform and raises the price target from $80 to $280.</p>


Upgrades

Daiwa Capital Upgrades AppLovin to Outperform, Raises Price Target to $280

<p>Suzuki Motor (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SZKMY#OTC">SZKMY</a>) reported quarterly earnings of $1.44 per share. This is a 61.8 percent increase over earnings of $0.89 per share from the same period last year.  The company reported $9.39 billion in sales this quarter. This is a 0.06 percent increase over sales of $9.38 billion the same period last year.</p>


SZKMY

Suzuki Motor Q2 EPS $1.44 Up From $0.89 YoY, Sales $9.39B Up From $9.38B YoY

<p>Docebo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCBO#NASDAQ">DCBO</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.21 by 28.57 percent.  The company reported quarterly sales of $55.433 million which beat the analyst consensus estimate of $54.147 million by 2.38 percent.  This is a 19.20 percent increase over sales of $46.506 million the same period last year.</p>


DCBO

Docebo Q3 2024 Adj. EPS $0.27 Beats $0.21 Estimate, Sales $55.433M Beat $54.147M Estimate

<p>Compass Point  analyst Merrill Ross   upgrades Innovative Ind Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Neutral to Buy and announces $125 price target.</p>


IIPR

Compass Point Upgrades Innovative Ind Props to Buy, Announces $125 Price Target

LAMR

Lamar Advertising Sees FY24 GAAP EPS Of $4.97-$4.99 (Estimate: $5.05), With Diluted AFFO Per Share Between $7.85-$7.95 (Prior View: $7.75-$7.90)

<p>Intl Cons Airlines Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ICAGY#OTC">ICAGY</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.55 by 12.73 percent. This is a 23.51 percent increase over earnings of $0.50 per share from the same period last year.  The company reported quarterly sales of $10.25 billion which beat the analyst consensus estimate of $9.98 billion by 2.74 percent.  This is a 8.95 percent increase over sales of $9.41 billion the same period last year.</p>


Internationalnsolidated Airlines Group Sponsored American Depository Receipt

ICAGY

Intl Cons Airlines Group Q3 EPS $0.62 Beats $0.55 Estimate, Sales $10.25B Beat $9.98B Estimate

Immix Biopharma Inc (IMMX) is around the middle of the Healthcare sector according to InvestorsObserver.IMMX received an overall rating of 49, which means that it scores higher than 49% of stocks. Additionally, Immix Biopharma Inc scored a 61 in the Healthcare sector, ranking it higher than 61% of stocks in that sector. IM

Will Immix Biopharma Inc (IMMX) Outperform the Rest of the Stocks in the Healthcare Sector?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Immix Biopharma reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/immx-stock-earnings-immix-biopharma-for-q4-of-2023/">IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Immix Biopharma reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -23 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/immx-stock-earnings-immix-biopharma-for-q1-of-2024/">IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024

Immix Biopharma, Inc. (IMMX) has shared an announcement. At Immix Biopharma, Inc.'s 2024 Annual Meeting, shareholders cast their votes on pivotal c...

Immix Biopharma Shareholders Back Growth and Governance Changes

Immix Biopharma, Inc. (IMMX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns. Robert Burns has given his Buy rati...

Buy Rating for Immix Biopharma Backed by Promising N-GENIUS Platform and Strong NXC-201 Sales Potential

Immix Biopharma doses first patient in U.S. AL amyloidosis trial

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Immix Biopharma, Inc. (IMMX – Research Report). The associated price ta...

Buy Rating Affirmed for Immix Biopharma Amid Promising NXC-201 Trial Outcomes and Market Potential

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Immix Biopharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/immx-stock-quote/"><strong>IMMX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Immix Biopharma reported earnings per share of -15 cents. This was above the analyst estimate for EPS of -21 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/immx-stock-earnings-immix-biopharma-for-q2-of-2024/">IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Equillium (EQ – Research Report), Foghorn Therapeuti...

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

Immix Biopharma, Inc. (IMMX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns f...

Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook

FHTX

IMMX

Press Releases

Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

Comments

Immix Biopharma

Notizie

Ultime notizie per Immix Biopharma (NASDAQ:IMMX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO